Basel Medical Group Ltd
BMGL
$0.61
$0.024.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.90% | 25.93% | 0.14% | 1.25% | 5.29% |
| Total Other Revenue | 1,462.50% | 1,412.50% | 212.50% | 212.50% | -105.00% |
| Total Revenue | 32.55% | 26.55% | 0.23% | 1.33% | 4.29% |
| Cost of Revenue | 59.77% | 52.54% | 52.10% | 53.77% | 54.34% |
| Gross Profit | -21.24% | -24.80% | -53.64% | -53.13% | -36.45% |
| SG&A Expenses | -- | -- | 3,650.00% | 3,691.67% | -100.00% |
| Depreciation & Amortization | 227.62% | 213.02% | 34.08% | 35.61% | 10.56% |
| Other Operating Expenses | 90.48% | 81.88% | 255.26% | 259.15% | 5,305.41% |
| Total Operating Expenses | 76.93% | 68.94% | 76.61% | 78.56% | 34.91% |
| Operating Income | -610.74% | -587.86% | -130.77% | -131.11% | -75.68% |
| Income Before Tax | -2,496.98% | -2,388.33% | -116.54% | -116.72% | -69.90% |
| Income Tax Expenses | -55.57% | -48.51% | -99.96% | -99.96% | -178.20% |
| Earnings from Continuing Operations | -1,539.72% | -1,474.53% | -124.19% | -124.45% | -37.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,539.64% | -1,474.50% | -124.19% | -124.45% | -37.40% |
| EBIT | -610.74% | -587.86% | -130.77% | -131.11% | -75.68% |
| EBITDA | -562.11% | -541.22% | -129.43% | -129.74% | -74.90% |
| EPS Basic | -1,195.29% | -1,149.71% | -124.09% | -124.42% | -37.27% |
| Normalized Basic EPS | -166.67% | -162.69% | -116.67% | -116.67% | -70.00% |
| EPS Diluted | -1,195.29% | -1,149.71% | -124.09% | -124.42% | -37.27% |
| Normalized Diluted EPS | -166.67% | -162.69% | -116.67% | -116.67% | -70.00% |
| Average Basic Shares Outstanding | 31.21% | 31.21% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 31.21% | 31.21% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |